Cellera Farma

Name

Cellera Farma

Legal name

CELLERA FARMACEUTICA S.A.

Website

https://cellerafarma.com.br

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Product Sales - Own Brands: Sale of proprietary pharmaceutical brands including Tylex, Pamelor, Concerta, Benerva, and supplements like Baristar, Convivia, Ossotrat. Revenue from direct product sales through pharmacy distribution network.
2. Licensing and Distribution Partnerships: Revenue from representing and distributing products from partners like Janssen (OTC portfolio), Sanofi (Puran, Zinpass Eze), Novartis (Pamelor), Bayer (Benerva). Cellera commercializes, distributes, and promotes these products in Brazil while original owners maintain ownership and production.
3. Commercial Representation: Commercial representation fees from managing partner pharmaceutical portfolios including sales, marketing, and distribution within Brazil.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Cellera Farma is a Brazilian pharmaceutical company that operates as a business hub for healthcare products through partnerships, licensing, distribution, promotion, and proprietary brands. The company manufactures, distributes, and commercializes prescription medications, OTC medications, and vitamin supplements across therapeutic areas including CNS/neurology, gastroenterology, orthopedics, and pediatrics. Its portfolio combines proprietary brands such as Tylex, Pamelor, Benerva, Baristar, and Convivia with licensing and distribution partnerships for major international products from Janssen, Sanofi, Novartis, Bayer, and Medley.

Product overview

Cellera Farma is a Brazilian pharmaceutical company operating as a business hub that connects health-focused partnerships, licensing, distribution, promotion, and proprietary products. The portfolio is organized across three main categories: (1) Prescription Medications covering CNS/neurology (Pamelor, Concerta, Invega, Risperdal, Tylex, Benerva, Mestinon), gastroenterology (Imosec, Motilium), orthopedics (Alendronato, Dermosalic), and cardiometabolic (Zinpass Eze, Puran); (2) OTC Medications including dermatologicals (Pioletal, Pioletal Plus, Tiadol, Tiaplex, Nemicina, Dermafree, Aceratum, Cetobeta, Cremderme, Lidial); and (3) Vitamins and Supplements including Baristar (multivitamin), Convivia (nootropic), Ossotrat-D/Ossotrat Plus (calcium+D), and Sulferrol (iron). Focus therapeutic areas include central nervous system, gastroenterology, orthopedics, and pediatrics.

Differentiator

Problem solved

Functional benefit

Brands

• Tylex: Opioid analgesic brand (Paracetamol + Codeína) with 40+ years market presence, second most prescribed brand with 12% prescription share.
• Pamelor
• Concerta
• Benerva
• Baristar
• Convivia
• Ossotrat-D
• Ossotrat Plus
• Sulferrol
• Mestinon
• Invega
• Risperdal
• Topamax
• Imosec
• Motilium

Products and services

• Tylex® Opioid analgesic combining Paracetamol with Codeína phosphate for pain relief. Market leader with 40+ years presence and second most prescribed brand (12% prescription share).
• Pamelor® Nortriptyline hydrochloride antidepressant, 34 years in market, neurology leader with 37% share (MAT 24) and 133% value growth since Cellera acquisition.
• Concerta® Methylphenidate hydrochloride for ADHD treatment. Achieved 3x prescription growth in 4 years of partnership, 14,000 new prescribers in 2023, 136% units growth.
• Benerva® Thiamine hydrochloride (Vitamin B1) supplement. Leader in prescription share category (56.2%) with 30%+ growth since acquisition.
• Invega® Paliperidone antipsychotic medication for schizophrenia treatment.
• Risperdal® Risperidone antipsychotic medication.
• Topamax® Topiramate medication for epilepsy and migraine treatment.
• Imosec® Loperamide hydrochloride for diarrhea treatment.
• Motilium® Domperidone for gastrointestinal motility disorders.
• Puran® Levothyroxine Sodium for hypothyroidism treatment. Acquired through Sanofi commercial partnership in 2026, marking entry into cardiometabolic category.
• Zinpass Eze® Rosuvastatin + Ezetimibe combination for dyslipidemia treatment. Acquired through Sanofi commercial partnership in 2026, marks entry into cardiometabolic category.
• Mestinon® Pyridostigmine bromide for myasthenia gravis treatment.
• Tandene® Combination analgesic with caffeine, carisoprodol, diclofenac sodium, and paracetamol.
• Tanderalgin® Prescription analgesic medication.
• Alendronato de Sódio Bisphosphonate for osteoporosis treatment.
• Amoxicilina + Clavulanato de Potássio Antibiotic combination for bacterial infections.
• Cetobeta® Topical cream/ointment with ketoconazole, betamethasone dipropionate, and neomycin sulfate.
• Cremderme® Topical corticosteroid with gentamicin, tolnaftate, and clioquinol.
• Dermosalic® Topical solution/ointment with betamethasone dipropionate and salicylic acid.
• Lidial® Lidocaine hydrochloride topical anesthetic.
• Meloxicam

Quantifiable outcome

• 133% value growth for Pamelor since acquisition
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Nine partnerships are on record, tiered core, minor and strategic.

• SanoficoreChannel Partner/ Reseller/ Distributor · 11 May 2026Commercial agreement for exclusive commercialization, distribution, and promotion of Puran (Levotiroxina Sódica) and Zinpass Eze (Rosuvastatina + Ezetimiba) starting June 1, 2026. Sanofi retains ownership and continues responsible for ANVISA registration and production. Marks Cellera's entry into cardiometabolic product category.
• Primavera SAFminorGTM or Marketing Partner · 1 January 2025Sports sponsorship partnership with Esporte Clube Primavera SAF, becoming official sponsor for Paulistão A1. Renewed for 2026 season, supporting the club's historic campaign.
• Tylex Rights AcquisitioncoreChannel Partner/ Reseller/ Distributor · 1 July 2023Strategic acquisition of Tylex brand rights to expand growth in the analgesic market. Tylex has been the expert in pain relief for over 40 years with 12% prescription share.
• MedleycoreChannel Partner/ Reseller/ Distributor · 1 June 2023Strategic partnership where two Medley products began being commercialized, distributed, and marketed by Cellera Farma.
• FerringstrategicStrategic or Co-development Partner · 1 June 2022Strategic partnership with Swiss pharmaceutical company Ferring for innovative medicines. Collaboration highlighted in Valor Econômico as part of Cellera's innovation strategy.
• JanssencoreChannel Partner/ Reseller/ Distributor · 1 December 2019Partnership for commercial representation of Janssen's OTC (Over-the-Counter) portfolio in Brazil. Cellera handles sales, marketing, and distribution of 12 established brand medications. This partnership drove revenue from R$140M to R$330M.
• Bayer Consumer Health BrasilcoreChannel Partner/ Reseller/ Distributor · 1 January 2019Acquisition of Benerva brand and rights from Bayer Consumer Health. Cellera obtained rights to this thiamine (Vitamin B1) product, which grew over 30% under Cellera's management.
• NovartiscoreChannel Partner/ Reseller/ Distributor · 1 December 2017Acquisition of Pamelor (cloridrato de nortriptilina) brand and intellectual property rights from Novartis. Cellera acquired marketing authorization, trademarks, and distribution rights for this established antidepressant brand.
• Kemin IndustriescoreTechnology or IntegrationSupplier partnership for Neumentix (Mentha spicata L.), a patented nootropic ingredient used in Convivia supplement. Neumentix is a registered trademark of Kemin Industries, Inc.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• EMS Pharma: Largest Brazilian generics manufacturer with broad prescription and OTC portfolio. Comparable incumbent that competes for retail pharmacy shelf access and physician detailing across the same therapeutic categories Cellera targets.
• Eurofarma Laboratórios: One of Brazil's largest pharmaceutical groups with branded generics, prescription, OTC, and export businesses across Latin America. Comparable as a top-tier Brazilian pharma incumbent in which Cellera competes for physician access and shelf space.
• Hypera Pharma: Largest Brazilian pharmaceutical company by revenue (formerly Hypermarcas) operating across OTC, generics, branded, and consumer health. Provides the strategic context for Cellera's Top-30 ambition; broad incumbent whose diversified portfolio dwarfs Cellera's specialty mix.
• Aché Laboratórios: Brazilian pharma leader with a broad prescription, OTC, and dermatology portfolio and significant investment in R&D. Comparable as a Top-10 Brazilian incumbent whose size and brand breadth contrasts with Cellera's lean, partnership-led model.

Direct peers

• Blau Farmacêutica: Brazilian specialty pharma with hospital, oncology, and specialty franchises; combines own portfolio with partnerships. Comparable to Cellera in lifecycle/brand acquisition approach at the mid-tier Brazilian scale.
• Momenta Farmacêutica: Brazilian specialty pharma with a similar lifecycle management focus on mature brands in CNS and other therapeutic areas. Closely comparable to Cellera in model (brand revitalization, licensing-led), therapeutic areas (CNS, neurology), and emerging-tier scale.
• Biolab Farmacêutica: Brazilian pharma company with strong CNS, cardiology, and women's health franchises built through licensing and brand acquisitions. Comparable to Cellera in mid-tier scale, brand-centric model, and reliance on partnerships with multinational pharma for Brazil commercialization.
• Apsen Farmacêutica: Brazilian specialty pharmaceutical company with a portfolio of established brands and focus on CNS, pain, and lifecycle management. Closest analogue to Cellera: both are mid-tier Brazilian labs that acquire, license, and revitalize mature brands from global pharma rather than competing via in-house R&D.
• Libbs Farmacêutica: Brazilian pharmaceutical company focused on specialty therapeutic areas including CNS, oncology, and women's health, with a portfolio of both own and partner brands. Comparable to Cellera in building a national brand presence through partnerships, licensing, and lifecycle management in Brazil.

Others

• Medley (Sanofi): Brazilian generics and branded pharma now owned by Sanofi, whose two products are currently being commercialized by Cellera itself. Relevant as both a partner (commercial representation agreement) and as a comparable Brazilian pharma; useful for understanding the partner/competitor overlap in Cellera's distribution universe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellera Farma